SG11202004151YA - Hydrophilic linkers for antibody drug conjugates - Google Patents

Hydrophilic linkers for antibody drug conjugates

Info

Publication number: SG11202004151YA
Authority: SG; Singapore
Prior art keywords: drug conjugates; antibody drug; hydrophilic linkers; linkers; hydrophilic
Prior art date: 2017-11-07

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-11-07Priority claimed from PCT/US2017/060434external-prioritypatent/WO2018089373A2/en

2018-11-06Application filed by Regeneron PharmafiledCriticalRegeneron Pharma

2020-06-29Publication of SG11202004151YApublicationCriticalpatent/SG11202004151YA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Botany (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG11202004151YA2017-11-072018-11-06Hydrophilic linkers for antibody drug conjugatesSG11202004151YA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
PCT/US2017/060434WO2018089373A2 (en)	2016-11-08	2017-11-07	Steroids and protein-conjugates thereof
US15/806,197US10711032B2 (en)	2016-11-08	2017-11-07	Steroids and protein-conjugates thereof
US201862669034P	2018-05-09	2018-05-09
PCT/US2018/059495WO2019094395A2 (en)	2017-11-07	2018-11-06	Hydrophilic linkers for antibody drug conjugates

Publications (1)

Publication Number	Publication Date
SG11202004151YAtrue SG11202004151YA (en)	2020-06-29

Family

ID=66439032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202004151YASG11202004151YA (en)	2017-11-07	2018-11-06	Hydrophilic linkers for antibody drug conjugates

Country Status (12)

Country	Link
US (1)	US12134631B2 (en)
EP (1)	EP3706805A2 (en)
JP (2)	JP7426931B2 (en)
KR (1)	KR20200085807A (en)
CN (1)	CN111601619A (en)
AU (1)	AU2018365946A1 (en)
CA (1)	CA3080857A1 (en)
EA (1)	EA202091135A1 (en)
IL (2)	IL313068A (en)
MX (1)	MX2020004691A (en)
SG (1)	SG11202004151YA (en)
WO (1)	WO2019094395A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112019009019A2 (en)	2016-11-08	2019-07-09	Regeneron Pharma	steroids and protein conjugates thereof
CA3063871A1 (en)	2017-05-18	2018-11-22	Regeneron Pharmaceuticals, Inc.	Cyclodextrin protein drug conjugates
CN118772242A (en)	2017-08-04	2024-10-15	拜斯科技术开发有限公司	CD137-specific bicyclic peptide ligand
IL313068A (en)	2017-11-07	2024-07-01	Regeneron Pharma	Hydrophilic linkers for antibody drug conjugates
AU2019205542A1 (en)	2018-01-08	2020-07-16	Regeneron Pharmaceuticals, Inc.	Steroids and antibody-conjugates thereof
EP3790899A1 (en)*	2018-05-09	2021-03-17	Regeneron Pharmaceuticals, Inc.	Anti-msr1 antibodies and methods of use thereof
CN113454097B (en)	2018-12-21	2024-08-30	里珍纳龙药品有限公司	Tubulysin and protein-tubulysin conjugates
CA3149482A1 (en)	2019-08-02	2021-02-11	Mersana Therapeutics, Inc.	Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
AU2021248635A1 (en)	2020-04-02	2022-10-27	Mersana Therapeutics, Inc.	Antibody drug conjugates comprising STING agonists
PH12023550032A1 (en)*	2020-06-24	2024-03-18	Regeneron Pharma	Tubulysins and protein-tubulysin conjugates
GB202011993D0 (en)	2020-07-31	2020-09-16	Adc Therapeutics Sa	ANTI-IL 13Ra2 antibodies
JP2023536192A (en)*	2020-08-03	2023-08-23	バイスクルテクス・リミテッド	peptide-based linker
CN113248436A (en)*	2021-04-13	2021-08-13	南京工业大学	Novel cross-linked molecule for protein targeted transportation and preparation method and application thereof
EP4349373A1 (en)	2021-06-01	2024-04-10	Ajinomoto Co., Inc.	Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
TW202320857A (en)*	2021-07-06	2023-06-01	美商普方生物製藥美國公司	Linkers, drug linkers and conjugates thereof and methods of using the same
WO2023222019A1 (en)*	2022-05-18	2023-11-23	成都百利多特生物药业有限责任公司	Ligand-drug conjugate and use thereof
AU2023310999A1 (en)	2022-07-21	2025-01-23	Firefly Bio, Inc.	Glucocorticoid receptor agonists and conjugates thereof
WO2024138000A1 (en)	2022-12-21	2024-06-27	Regeneron Pharmaceuticals, Inc.	Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
AR131524A1 (en)*	2022-12-29	2025-03-26	Beigene Ltd	B7H3 Antibody-Drug Conjugates
WO2025067306A1 (en)*	2023-09-26	2025-04-03	信达生物制药(苏州)有限公司	Antibody-drug conjugate targeting her3

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2920999A (en)	1957-06-07	1960-01-12	Pfizer & Co C	21-nitrogen derivatives of corticosteroids
DE1165595B (en)	1958-03-04	1964-03-19	Olin Mathieson	Process for the preparation of triamcinolone acetonide-21-hemisuccinate and its salts
GB889766A (en)	1958-03-04	1962-02-21	Olin Mathieson	Improvements in steroids and the synthesis thereof
US3197469A (en)	1958-08-06	1965-07-27	Pharmaceutical Res Products In	16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3007923A (en)	1959-01-22	1961-11-07	Lab Francais Chimiotherapie	Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB898295A (en)	1959-03-18	1962-06-06	Upjohn Co	Improvements in or relating to steroids and the manufacture thereof
US3033874A (en)	1960-05-11	1962-05-08	Pfizer & Co C	17beta-propenoyl steroids and process for preparing same
US3033873A (en)	1960-05-11	1962-05-08	Pfizer & Co C	21-aminomethyl-pregnenes
US3020275A (en)	1960-06-07	1962-02-06	American Cyanamid Co	21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
DE1169444B (en)	1961-02-22	1964-05-06	Schering Ag	Process for the preparation of ?-16ª‡-methyl steroids
US3047468A (en)	1961-06-06	1962-07-31	American Cyanamid Co	Method of preparing delta1, 4-3-keto steroids of the pregnane series
US3383394A (en)	1965-08-30	1968-05-14	Schering Corp	Novel 17-acylating process and products thereof
US3798216A (en)	1969-03-07	1974-03-19	Fabrication Des Antibiotique S	9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof
DE2047105C3 (en)	1970-09-18	1979-02-15	Schering Ag, 1000 Berlin Und 4619 Bergkamen	17-chloro steroids and process for their preparation
IT1057859B (en)	1972-04-28	1982-03-30	Sigma Tao Ind Farmaceutiche Sp	Triamcinolone derivs - as antiinflammatory agents
SE378110B (en)	1972-05-19	1975-08-18	Bofors Ab
SE378109B (en)	1972-05-19	1975-08-18	Bofors Ab
US4076737A (en)	1975-02-20	1978-02-28	Ciba-Geigy Corporation	Aldehydes of the pregnane series and derivatives thereof
IL73337A (en)	1984-10-28	1988-09-30	Yissum Res Dev Co	Antitumor steroid-platinum complexes and method for the preparation thereof
SE8604059D0 (en)	1986-09-25	1986-09-25	Astra Pharma Prod	A METHOD OF CONTROLLING THE EPIMERIC DISTRIBUTION IN THE PREPARATION OF 16,17-ACETALS OF PREGNANE DERIVATIVES
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5116829A (en)	1990-04-23	1992-05-26	Kao Corporation	Steroid compounds
US5183815A (en)	1991-01-22	1993-02-02	Merck & Co., Inc.	Bone acting agents
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
CA2152374A1 (en)	1993-01-08	1994-07-21	Ralph Lennart Brattsand	Novel colon- or ileum-specific steroid derivatives
DE4311987A1 (en)	1993-04-07	1994-10-13	Schering Ag	New glucocorticoids
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5837698A (en)	1996-05-02	1998-11-17	G. D. Searle & Co.	Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
WO2000049993A2 (en)	1999-02-24	2000-08-31	Nitromed, Inc.	Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US20070258987A1 (en)	2000-11-28	2007-11-08	Seattle Genetics, Inc.	Recombinant Anti-Cd30 Antibodies and Uses Thereof
SE0101220D0 (en)	2001-04-04	2001-04-04	Astrazeneca Ab	New use
US6908934B2 (en)	2001-06-11	2005-06-21	Merck & Co., Inc.	Therapeutic compounds for treating dyslipidemic conditions
ITMI20020148A1 (en)	2002-01-29	2003-07-29	Nicox Sa	NEW CORTICOSTEROIDS
US20050009798A1 (en)	2002-02-20	2005-01-13	Sepracor Inc.	Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
DK1545613T3 (en)	2002-07-31	2011-11-14	Seattle Genetics Inc	Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease
US20040157810A1 (en)	2002-08-23	2004-08-12	Teicher Martin H.	Corticosteroid conjugates and uses thereof
MXPA05002444A (en)	2002-09-06	2005-09-30	Insert Therapeutics Inc	Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto.
CN1414008A (en)	2002-10-17	2003-04-30	南开大学	Steroid compound containing nitrogen and its preparation method
US7015349B2 (en)	2003-03-26	2006-03-21	The Gillette Company	Reduction of hair growth
SG10201701737XA (en)	2003-11-06	2017-04-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2005063777A1 (en)	2003-12-23	2005-07-14	Corus Pharma	Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
WO2005079523A2 (en)	2004-02-18	2005-09-01	University Of Georgia Research Foundation, Inc.	Novel teleost derived antimicrobal polypeptides
US20050192257A1 (en)	2004-02-26	2005-09-01	Peyman Gholam A.	Predictors for patients at risk for glaucoma from steroid therapy
AR048098A1 (en)	2004-03-15	2006-03-29	Wyeth Corp	CALIQUEAMYCIN CONJUGATES
EP1753463A2 (en)	2004-06-01	2007-02-21	Genentech, Inc.	Antibody drug conjugates and methods
EP1602931A1 (en)	2004-06-03	2005-12-07	Universiteit Leiden	SR-A antagonists
US7541330B2 (en)*	2004-06-15	2009-06-02	Kosan Biosciences Incorporated	Conjugates with reduced adverse systemic effects
ES2315600T3 (en)	2004-08-09	2009-04-01	Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts	ALBUMINE CONJUGATES CONTAINING A GLUCURONIC BINDER.
TW200616604A (en)	2004-08-26	2006-06-01	Nicholas Piramal India Ltd	Nitric oxide releasing prodrugs containing bio-cleavable linker
EP1817341A2 (en)	2004-11-29	2007-08-15	Seattle Genetics, Inc.	Engineered antibodies and immunoconjugates
WO2006135371A1 (en)	2005-06-09	2006-12-21	Kosan Biosciences Incorporated	Conjugates with reduced adverse systemic effects
RU2008100237A (en)	2005-06-14	2009-07-20	Джилид Сайэнс, Инк. (US)	GENERAL MEDICINAL FORMS OF STEROIDS AND β-AGONISTS (OPTIONS), INCLUDING THEIR AEROSOL COMPOSITION (OPTIONS) AND METHOD FOR PREVENTING AND / OR TREATING PULMONARY INFLAMMATION AND / OR IMPLEMENTING
US7750116B1 (en)	2006-02-18	2010-07-06	Seattle Genetics, Inc.	Antibody drug conjugate metabolites
WO2008127347A1 (en)	2006-07-21	2008-10-23	Diadexus, Inc.	Pro115 antibody compositions and methods of use
MX2009008334A (en)	2007-02-05	2009-08-12	Nicox Sa	Nitric oxide releasing steroids.
WO2008122039A2 (en)	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selenocysteine mediated hybrid antibody molecules
DK2167963T3 (en)	2007-05-23	2019-06-24	Ventana Med Syst Inc	Polymer carriers for immunohistochemistry and in situ hybridization
JP5690589B2 (en)	2007-06-25	2015-03-25	エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ，Ｉｎｃ．	Conjugates containing hydrophilic spacer linkers
WO2009001364A2 (en)	2007-06-28	2008-12-31	Capsutech Ltd	Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
CN101397328A (en)	2007-09-27	2009-04-01	天津药业研究院有限公司	Nitric oxide-releasing glucocorticosteroid
HUE055815T2 (en)	2007-10-05	2021-12-28	Univ Wayne State	Dendrimers for sustained release of compounds
WO2009085879A2 (en)	2007-12-21	2009-07-09	Schering Corporation	C20-c21 substituted glucocorticoid receptor agonists
EP2235035A2 (en)	2007-12-21	2010-10-06	Schering Corporation	C-21 thioethers as glucocorticoid receptor agonists
KR20100137585A (en)	2008-04-30	2010-12-30	이뮤노젠 아이엔씨	Strong Complexes and Hydrophilic Linkers
EP2294077A1 (en)	2008-06-10	2011-03-16	Gilead Sciences, Inc.	Corticosteroid linked beta-agonist compounds for use in therapy
PL2326349T3 (en)	2008-07-21	2015-08-31	Polytherics Ltd	Novel reagents and method for conjugating biological molecules
EP2313436B1 (en)	2008-07-22	2014-11-26	Ablynx N.V.	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
AU2010221972B2 (en)	2009-03-09	2012-07-05	Mikasa Seiyaku Co., Ltd.	Steroid compound
WO2010126953A1 (en)	2009-04-29	2010-11-04	Gilead Sciences, Inc.	Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en)	2009-05-15	2010-11-18	Gilead Sciences, Inc.	Corticosteroid beta-agonist compounds for use in therapy
CA2770626A1 (en)	2009-08-10	2011-02-17	Mark Smith	Functionalisation of solid substrates
WO2011020107A2 (en)	2009-08-14	2011-02-17	Georgetown University	Compositions and methods for detection and treatment of breast cancer
GB0917054D0 (en)	2009-09-29	2009-11-11	Cytoguide As	Agents, uses and methods
GB0917044D0 (en)	2009-09-29	2009-11-18	Cytoguide As	Agents, uses and methods
WO2011081937A1 (en)	2009-12-15	2011-07-07	Gilead Sciences, Inc.	Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
WO2011090940A1 (en)	2010-01-19	2011-07-28	Cerulean Pharma Inc.	Cyclodextrin-based polymers for therapeutic delivery
CN102844050B (en)	2010-02-19	2019-02-05	康奈尔大学	Treatment of autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
EP2528625B1 (en)	2010-04-15	2013-07-10	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (en)	2010-07-06	2012-01-12	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Reporter for rna polymerase ii termination
US9023858B2 (en)	2010-07-23	2015-05-05	Takeda Pharmaceutical Company Limited	Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors
LT2601298T (en)	2010-08-02	2017-03-10	Regeneron Pharmaceuticals, Inc.	Mice that make binding proteins comprising vl domains
RS53519B1 (en)	2010-09-01	2015-02-27	Bayer Intellectual Property Gmbh	N-(tetrazol-5-yl)- and n-(triazol-5-yl)aryl carboxylic acid amides and use of same as herbicides
JP5828902B2 (en)	2010-10-29	2015-12-09	イミュノジェン，インコーポレイテッド	Non-antagonistic EGFR binding molecules and immune complexes thereof
US20120302505A1 (en)	2011-04-21	2012-11-29	Fetzer Oliver S	Cyclodextrin-based polymers for therapeutic delivery
CN110078788B (en)	2011-05-27	2021-08-06	Ambrx 公司	Dolastatin derivatives containing unnatural amino acid linkages
CN103702996A (en)	2011-05-27	2014-04-02	Ambrx公司	Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en)	2011-06-10	2014-08-26	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
EP2751076B1 (en)	2011-10-14	2018-04-25	MedImmune Limited	Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
JP6170497B2 (en)	2011-10-14	2017-07-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	Pyrrolobenzodiazepine
CN103987384A (en)	2011-10-14	2014-08-13	西雅图基因公司	Pyrrolobenzodiazepines and targeted conjugates
KR101961976B1 (en)	2011-10-14	2019-03-25	시애틀 지네틱스, 인크.	Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en)	2011-11-11	2013-05-16	Pfizer Inc.	Antibody-drug conjugates
US20130224228A1 (en)	2011-12-05	2013-08-29	Igenica, Inc.	Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
GB201122325D0 (en)	2011-12-23	2012-02-01	Cytoguide As	Novel formulations
MX361875B (en)	2012-03-14	2018-12-18	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof.
MX2014015205A (en)	2012-06-14	2015-08-14	Ambrx Inc	Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides.
RU2682676C2 (en)	2012-10-11	2019-03-20	Асцендис Фарма Ас	Diagnosis, prevention and treatment of joint diseases
MX2015004757A (en)	2012-10-16	2015-07-17	Endocyte Inc	Drug delivery conjugates containing unnatural amino acids and methods for using.
FI3912642T3 (en)	2012-10-23	2023-07-07	Synaffix Bv	Modified antibody, antibody-conjugate and process for the preparation thereof
US9376420B2 (en)	2012-10-25	2016-06-28	Yuhan Corporation	4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
CN105102480B (en)	2012-12-24	2019-04-16	艾伯维公司	Hprl receptor binding protein and application thereof
CN105189546B (en)	2013-03-13	2022-09-02	西雅图基因公司	Cyclodextrin and antibody-drug conjugate formulations
AU2014233385C1 (en)	2013-03-15	2019-09-19	Regeneron Pharmaceuticals, Inc.	Biologically active molecules, conjugates thereof, and therapeutic uses
US20160082119A1 (en)	2013-04-22	2016-03-24	Avelas Biosciences, Inc.	Selective drug delivery compositions and methods of use
WO2014197854A1 (en)	2013-06-06	2014-12-11	Igenica Biotherapeutics, Inc.	Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
AU2014283185B2 (en)	2013-06-21	2019-05-02	Araris Biotech Ltd.	Enzymatic conjugation of polypeptides
JPWO2015005459A1 (en)	2013-07-10	2017-03-02	生化学工業株式会社	Pharmaceutical composition for respiratory administration
TWI641620B (en)	2013-08-21	2018-11-21	再生元醫藥公司	Anti-prlr antibodies and uses thereof
BR112016004023A2 (en)	2013-08-26	2022-11-16	Regeneron Pharma	COMPOSITION, METHODS FOR PREPARING A COMPOSITION AND FOR TREATMENT OF A DISEASE, AND COMPOUND
DK3057585T3 (en)*	2013-10-15	2020-10-19	Seagen Inc	PEGYLED MEDICINE LINKERS FOR IMPROVED LIGAND MEDICINE CONJUGATE PHARMACOKINETICS
CN103694375B (en)	2013-12-13	2016-10-05	北京大学	A kind of triterpene-cyclodextcovalent covalent compound and its production and use
CA2937386C (en)	2014-01-24	2023-07-18	Centre National De La Recherche Scientifique	Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating e. coli induced inflammatory bowel diseases such as crohn's disease
EP3125943A4 (en)	2014-04-04	2017-12-06	Merck Sharp & Dohme Corp.	Phosphate based linkers for intracellular delivery of drug conjugates
PT3789042T (en)	2014-04-10	2025-01-14	Daiichi Sankyo Europe Gmbh	Method for producing anti-her3 antibody-drug conjugate
JP6800021B2 (en)*	2014-06-02	2020-12-16	レゲネロンファーマシューティカルス，インコーポレーテッド	Antibody-drug conjugates, their manufacture, and their therapeutic uses
EP3166638A1 (en)	2014-06-13	2017-05-17	Glykos Finland Oy	Payload-polymer-protein conjugates
EP3226908A1 (en)*	2014-12-03	2017-10-11	F.Hoffmann-La Roche Ag	Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
KR20170086536A (en)*	2014-12-03	2017-07-26	제넨테크, 인크.	Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
EP3230282A1 (en)	2014-12-09	2017-10-18	AbbVie Inc.	Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
CN111620862A (en)*	2014-12-09	2020-09-04	艾伯维公司	BCL-XL-inhibitory compounds and antibody drug conjugates including the same
WO2016120891A1 (en)	2015-01-30	2016-08-04	Coral Drugs Pvt. Ltd.	Novel process for preparation of glucocorticoid steroids
CA2976064A1 (en)	2015-02-06	2016-08-11	Sorrento Therapeutics, Inc.	Antibody drug conjugates
BR112017020149A8 (en)	2015-03-27	2023-05-02	Regeneron Pharma	MAITANSINOID DERIVATIVES, CONJUGATES THEREOF AND METHODS OF USE
KR20180025865A (en)	2015-07-06	2018-03-09	리제너론 파마슈티칼스 인코포레이티드	Multispecific antigen binding molecules and uses thereof
WO2017006279A1 (en)	2015-07-08	2017-01-12	Aten Porus Lifesciences	Cyclodextrin-polymer complexes and compostions and methods of making and using the same
CN108135857A (en)	2015-09-10	2018-06-08	沙思奇公司	bio-orthogonal composition
EP3359194A4 (en)	2015-10-06	2019-04-24	Merck Sharp & Dohme Corp.	ANTIBODY-MEDICINAL CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
CN108779127B (en)	2016-01-25	2022-07-05	里珍纳龙药品有限公司	Maytansinoid derivatives, conjugates thereof, and methods of use
WO2017132103A2 (en)	2016-01-29	2017-08-03	Merck Sharp & Dohme Corp.	Phosphonate linkers and their use to facilitate cellular retention of compounds
US11786603B2 (en)	2016-02-26	2023-10-17	Regeneron Pharmaceuticals, Inc.	Optimized transglutaminase site-specific antibody conjugation
KR20180134351A (en)*	2016-03-25	2018-12-18	시애틀 지네틱스, 인크.	Process for the preparation of pegylated drug-linkers and intermediates thereof
GB201608936D0 (en)	2016-05-20	2016-07-06	Polytherics Ltd	Novel conjugates and novel conjugating reagents
US20180126000A1 (en)	2016-06-02	2018-05-10	Abbvie Inc.	Glucocorticoid receptor agonist and immunoconjugates thereof
EP3468599A2 (en)*	2016-06-08	2019-04-17	AbbVie Inc.	Anti-cd98 antibodies and antibody drug conjugates
MA46417A (en)	2016-09-23	2019-07-31	Regeneron Pharma	ANTI-STEAP2 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO STEAP2 AND CD3, AND THEIR USES
BR112019009019A2 (en)	2016-11-08	2019-07-09	Regeneron Pharma	steroids and protein conjugates thereof
RU2022101392A (en)	2017-02-28	2022-03-02	Иммуноджен, Инк.	MAITANZINOID DERIVATIVES WITH SELF-REDUCING PEPTIDE LINKERS AND THEIR CONJUGATES
CA3063871A1 (en)	2017-05-18	2018-11-22	Regeneron Pharmaceuticals, Inc.	Cyclodextrin protein drug conjugates
JP2020520926A (en)	2017-05-18	2020-07-16	レゲネロンファーマシューティカルス，インコーポレーテッド	Bis-octahydrophenanthrene carboxamide and protein conjugate thereof
CN111065623B9 (en)	2017-05-24	2024-10-25	德克萨斯州大学系统董事会	Linker for antibody drug conjugates
CN108853514B (en)	2017-08-18	2022-07-22	四川百利药业有限责任公司	Antibody drug conjugates with two different drugs
WO2019034176A1 (en)	2017-08-18	2019-02-21	四川百利药业有限责任公司	Camptothecin-antibody conjugate
IL313068A (en)	2017-11-07	2024-07-01	Regeneron Pharma	Hydrophilic linkers for antibody drug conjugates
AU2019205542A1 (en)	2018-01-08	2020-07-16	Regeneron Pharmaceuticals, Inc.	Steroids and antibody-conjugates thereof
MX2020010458A (en)	2018-04-06	2021-01-29	Seattle Genetics Inc	Camptothecin peptide conjugates.
EP3790899A1 (en)	2018-05-09	2021-03-17	Regeneron Pharmaceuticals, Inc.	Anti-msr1 antibodies and methods of use thereof
MA54545A (en)	2018-12-21	2021-10-27	Regeneron Pharma	RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATE THEREOF
MA59295B1 (en)	2019-01-08	2024-10-31	Regeneron Pharmaceuticals, Inc.	TRACELESS LINKERS AND ASSOCIATED PROTEIN CONJUGATES
US20230119539A1 (en)	2019-01-08	2023-04-20	Regeneron Pharmaceuticals, Inc.	Traceless linkers and protein-conjugates thereof

2018
- 2018-11-06ILIL313068Apatent/IL313068A/enunknown
- 2018-11-06CACA3080857Apatent/CA3080857A1/enactivePending
- 2018-11-06KRKR1020207015856Apatent/KR20200085807A/enactivePending
- 2018-11-06EAEA202091135Apatent/EA202091135A1/enunknown
- 2018-11-06USUS16/761,493patent/US12134631B2/enactiveActive
- 2018-11-06WOPCT/US2018/059495patent/WO2019094395A2/enunknown
- 2018-11-06AUAU2018365946Apatent/AU2018365946A1/enactivePending
- 2018-11-06ILIL274427Apatent/IL274427B2/enunknown
- 2018-11-06CNCN201880085150.3Apatent/CN111601619A/enactivePending
- 2018-11-06EPEP18803845.9Apatent/EP3706805A2/enactivePending
- 2018-11-06MXMX2020004691Apatent/MX2020004691A/enunknown
- 2018-11-06JPJP2020524502Apatent/JP7426931B2/enactiveActive
- 2018-11-06SGSG11202004151YApatent/SG11202004151YA/enunknown
2024
- 2024-01-23JPJP2024007898Apatent/JP2024045283A/enactivePending

Also Published As

Publication number	Publication date
CN111601619A (en)	2020-08-28
US12134631B2 (en)	2024-11-05
KR20200085807A (en)	2020-07-15
JP2021502341A (en)	2021-01-28
IL274427B2 (en)	2024-11-01
CA3080857A1 (en)	2019-05-16
MX2020004691A (en)	2020-08-20
WO2019094395A3 (en)	2019-08-22
EP3706805A2 (en)	2020-09-16
JP2024045283A (en)	2024-04-02
JP7426931B2 (en)	2024-02-02
AU2018365946A1 (en)	2020-05-14
IL313068A (en)	2024-07-01
IL274427A (en)	2020-06-30
IL274427B1 (en)	2024-07-01
EA202091135A1 (en)	2020-10-14
WO2019094395A2 (en)	2019-05-16
US20210332080A1 (en)	2021-10-28

Publication	Publication Date	Title
IL274427A (en)	2020-06-30	Hydrophilic linkers for antibody drug conjugates
IL291073A (en)	2022-05-01	Anti-egfr antibody drug conjugates
IL267003A (en)	2019-07-31	Multi-drug antibody drug conjugates
IL267834A (en)	2019-09-26	Anti-ccr7 antibody drug conjugates
IL263600A (en)	2019-01-31	Anti-b7-h3 antibodies and antibody drug conjugates
HK1232123A1 (en)	2018-01-05	Hydrophilic antibody drug conjugates
IL250319A0 (en)	2017-03-30	Stability-modulating linkers for use with antibody drug conjugates
IL259651A (en)	2018-08-30	Site specific her2 antibody drug conjugates
EP3307749A4 (en)	2019-06-19	Hydrophilic linkers for conjugation
IL274650A (en)	2020-06-30	Anti-cd40 antibody drug conjugates
EP3250238A4 (en)	2018-09-19	Antibody drug conjugates
EP3253212A4 (en)	2018-09-19	Antibody drug conjugates
IL287938A (en)	2022-01-01	Antibody drug conjugates
IL287596A (en)	2021-12-01	Antibody drug conjugates having linkers comprising hydrophilic groups
PT3271329T (en)	2021-10-25	Novel hydrophilic linkers and ligand-drug conjugates thereof
IL313805A (en)	2024-08-01	Antibody drug conjugates
ZA202103478B (en)	2022-12-21	Antibody drug conjugates comprising ecteinascidin derivatives
PT3544634T (en)	2021-06-02	Met antibody drug conjugates
LU92659B1 (en)	2016-08-24	Glycooptimized antibody drug conjugates
IL268245A (en)	2019-09-26	Calicheamicin derivatives and antibody drug conjugates thereof
EP3638309A4 (en)	2021-03-24	Antibody drug conjugates that bind lgr5

Movatterモバイル変換

SG11202004151YA - Hydrophilic linkers for antibody drug conjugates - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=66439032

Family Applications (1)

Country Status (12)

Families Citing this family (20)

Family Cites Families (152)

Also Published As

Similar Documents